JP2021523225A5 - - Google Patents

Info

Publication number
JP2021523225A5
JP2021523225A5 JP2021510283A JP2021510283A JP2021523225A5 JP 2021523225 A5 JP2021523225 A5 JP 2021523225A5 JP 2021510283 A JP2021510283 A JP 2021510283A JP 2021510283 A JP2021510283 A JP 2021510283A JP 2021523225 A5 JP2021523225 A5 JP 2021523225A5
Authority
JP
Japan
Prior art keywords
compound according
group
formula
compound
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021510283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523225A (ja
JP7379467B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030473 external-priority patent/WO2019213445A1/en
Publication of JP2021523225A publication Critical patent/JP2021523225A/ja
Publication of JP2021523225A5 publication Critical patent/JP2021523225A5/ja
Application granted granted Critical
Publication of JP7379467B2 publication Critical patent/JP7379467B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510283A 2018-05-03 2019-05-02 Rip1阻害剤化合物並びにそれを製造及び使用するための方法 Active JP7379467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666452P 2018-05-03 2018-05-03
US62/666,452 2018-05-03
PCT/US2019/030473 WO2019213445A1 (en) 2018-05-03 2019-05-02 Rip1 inhibitory compounds and methods for making and using the same

Publications (3)

Publication Number Publication Date
JP2021523225A JP2021523225A (ja) 2021-09-02
JP2021523225A5 true JP2021523225A5 (cg-RX-API-DMAC7.html) 2022-04-13
JP7379467B2 JP7379467B2 (ja) 2023-11-14

Family

ID=66554488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510283A Active JP7379467B2 (ja) 2018-05-03 2019-05-02 Rip1阻害剤化合物並びにそれを製造及び使用するための方法

Country Status (38)

Country Link
US (3) US10975064B2 (cg-RX-API-DMAC7.html)
EP (1) EP3788045B1 (cg-RX-API-DMAC7.html)
JP (1) JP7379467B2 (cg-RX-API-DMAC7.html)
KR (1) KR102823195B1 (cg-RX-API-DMAC7.html)
CN (1) CN112384510B (cg-RX-API-DMAC7.html)
AU (1) AU2019262142B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020022423A2 (cg-RX-API-DMAC7.html)
CA (1) CA3099018A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002840A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020015153A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200582A (cg-RX-API-DMAC7.html)
CY (1) CY1126152T1 (cg-RX-API-DMAC7.html)
DK (1) DK3788045T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2020000197A (cg-RX-API-DMAC7.html)
EA (1) EA202092581A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20077518A (cg-RX-API-DMAC7.html)
ES (1) ES2947446T3 (cg-RX-API-DMAC7.html)
FI (1) FI3788045T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230909T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062277T2 (cg-RX-API-DMAC7.html)
IL (1) IL278416B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20200277B1 (cg-RX-API-DMAC7.html)
LT (1) LT3788045T (cg-RX-API-DMAC7.html)
MA (1) MA52492B1 (cg-RX-API-DMAC7.html)
MD (1) MD3788045T2 (cg-RX-API-DMAC7.html)
MX (1) MX2020011622A (cg-RX-API-DMAC7.html)
MY (1) MY205388A (cg-RX-API-DMAC7.html)
PE (1) PE20210414A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551848A1 (cg-RX-API-DMAC7.html)
PL (1) PL3788045T3 (cg-RX-API-DMAC7.html)
PT (1) PT3788045T (cg-RX-API-DMAC7.html)
RS (1) RS64418B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202010913PA (cg-RX-API-DMAC7.html)
SI (1) SI3788045T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300203T1 (cg-RX-API-DMAC7.html)
UA (1) UA128160C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019213445A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202007487B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3788045T3 (pl) * 2018-05-03 2023-10-09 Rigel Pharmaceuticals, Inc. Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
SI3788044T1 (sl) 2018-05-03 2023-12-29 Rigel Pharmaceuticals, Inc. Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo
BR112021009610A2 (pt) 2018-11-20 2021-08-10 Sironax Ltd composto, composição farmacêutica, uso de um composto ou composição, e, método de inibir necrose, ferroptose, rip1 humana ou indicações relacionadas
US11718612B2 (en) 2019-09-06 2023-08-08 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
ES3043457T3 (en) * 2019-09-06 2025-11-25 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
AU2020341708B2 (en) 2019-09-06 2024-01-04 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
SMT202600151T1 (it) * 2019-11-07 2026-05-12 Rigel Pharmaceuticals Inc Composti eterociclici inibitori di rip1
AU2020391425A1 (en) * 2019-11-26 2022-06-16 Board Of Regents, The University Of Texas System Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI824259B (zh) 2020-07-01 2023-12-01 美商雷傑製藥公司 Rip1k抑制劑
EP4200281A4 (en) * 2020-08-18 2024-09-25 Hutchison Medipharma Limited PYRIMIDINONE COMPOUNDS AND THEIR USES
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
WO2022237890A1 (zh) * 2021-05-14 2022-11-17 中国医药研究开发中心有限公司 氮杂卓类稠环化合物及其医药用途
CN115894489A (zh) * 2021-09-22 2023-04-04 中国药科大学 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用
US20240425524A1 (en) * 2021-10-27 2024-12-26 Merck Sharp & Dohme Llc Spirotricycle ripk1 inhibitors and methods of uses thereof
KR20230100646A (ko) * 2021-12-24 2023-07-05 제일약품주식회사 Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
JP2025510009A (ja) * 2022-02-28 2025-04-14 シロナックス リミテッド. Rip1調節物質、その調製、及び使用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
CA2031376A1 (en) 1989-12-04 1991-06-05 Bahram Farhadieh Single layer transdermal drug administration system
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
CA2123809A1 (en) 1991-12-18 1993-06-24 Debra L. Wilfong Multilayered barrier structures
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
CA2696349A1 (en) 2007-08-15 2009-02-19 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
TWI648274B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 (二)
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
RU2017109122A (ru) * 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
EP3256467A1 (en) 2015-02-13 2017-12-20 GlaxoSmithKline Intellectual Property Management Limited Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
RU2716136C2 (ru) * 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
WO2017064217A1 (en) 2015-10-13 2017-04-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis
WO2017069279A1 (ja) 2015-10-23 2017-04-27 武田薬品工業株式会社 複素環化合物
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ. ホフマン-ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3585782A1 (en) 2017-02-27 2020-01-01 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
SI3788044T1 (sl) 2018-05-03 2023-12-29 Rigel Pharmaceuticals, Inc. Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo
PL3788045T3 (pl) 2018-05-03 2023-10-09 Rigel Pharmaceuticals, Inc. Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
WO2020001420A1 (zh) 2018-06-26 2020-01-02 中国科学院上海有机化学研究所 一类细胞坏死抑制剂及其制备方法和用途
JP7045526B2 (ja) 2018-11-02 2022-03-31 中国科学院上海薬物研究所 Rip1キナーゼを阻害する複素環状アミド及びその使用
ES3043457T3 (en) 2019-09-06 2025-11-25 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
AU2020341708B2 (en) 2019-09-06 2024-01-04 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
SMT202600151T1 (it) * 2019-11-07 2026-05-12 Rigel Pharmaceuticals Inc Composti eterociclici inibitori di rip1
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k

Similar Documents

Publication Publication Date Title
TWI843372B (zh) 用於降解突變kras蛋白之化合物及其應用
TWI844568B (zh) 抑制shp2活性化合物之製造方法、及由酸加成產生之產物
ES2453372T3 (es) Derivados de oxadiazol como agonistas de S1P1
HRP20230909T1 (hr) Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
AU2018200461B2 (en) Process methods for phosphatidylinositol 3-kinase inhibitors
BR112020018064A2 (pt) Compostos de aminoácidos e métodos de uso
JP2018515581A5 (cg-RX-API-DMAC7.html)
JP7187575B2 (ja) Rhoキナーゼ阻害剤としてのベンゾピラゾール系化合物
JP2004506611A5 (cg-RX-API-DMAC7.html)
JP2018515573A (ja) 複素環化合物の合成
UA127769C2 (uk) Похідні хіноліну як інгібітори інтегрину альфа-4-бета-7
JP2009538910A5 (cg-RX-API-DMAC7.html)
JP2024530111A (ja) アフィカムテンを調製するための工程
EP4329755A1 (en) Expanded dosage regimens for integrin inhibitors
TW202122393A (zh) 吡唑化合物,其配製物以及使用該化合物和/或配製物之方法
JP4393376B2 (ja) フェニルシクロヘキシルプロパノールアミン誘導体、その製造法、およびその治療的適用
RU2011101661A (ru) Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний
JP2021515018A (ja) 可溶性グアニル酸シクラーゼ刺激薬を調製するための方法
JP2016538337A5 (cg-RX-API-DMAC7.html)
BR122025028707A2 (pt) Métodos para produção de compostos para inibir atividade de shp2
HK40131580A (en) Heteroaromatic dhodh inhibitors
HK40095791A (en) Process of manufacture of a compound for inhibiting the activity of shp2
JP4782441B2 (ja) ジフェニルメチルピペラジン誘導体及びそれを含有する医薬組成物
CN120923507A (zh) 一种喹唑啉酮大环化合物及其制备方法和应用
CN116209440A (zh) 化合物的制造方法